A private investment group acquired an unknown stake in IOI, LLC from Prospect Park Capital Corp. (TSXV:PPK) for $0.16 million in cash on November 9, 2015. Prospect Park has received its initial capital returned $0.15 million plus an 8% return of $0.012 million and the retained ability to collect an additional 32% should the Serenity drug successfully receive approval by the United States Food and Drug Administration.


A private investment group completed the acquisition of an unknown stake in IOI, LLC from Prospect Park Capital Corp. (TSXV:PPK) on November 9, 2015. As announced on March 29, 2017, Prospect Park Capital will not receive its previously announced milestone as Allergan exercised its unilateral right to terminate its license, transfer and development agreement with Serenity which effectively terminated Serenity's (and its partners) right to any milestone payments.